Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 27.50 GBp
Change Today 0.00 / 0.00%
Volume 2.5K
ETX On Other Exchanges
As of 11:30 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

e-therapeutics plc (ETX) Snapshot

27.50 GBp
Previous Close
27.50 GBp
Day High
27.50 GBp
Day Low
27.50 GBp
52 Week High
02/26/15 - 49.00 GBp
52 Week Low
01/7/15 - 26.00 GBp
Market Cap
Average Volume 10 Days
-0.03 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for E-THERAPEUTICS PLC (ETX)

Related News

No related news articles were found.

e-therapeutics plc (ETX) Related Businessweek News

No Related Businessweek News Found

e-therapeutics plc (ETX) Details

e-Therapeutics plc engages in the discovery and development of drugs through its proprietary platform in network pharmacology. The company focuses on the discovery of drugs for cancer and central nervous system disorders. Its drug candidates include ETS2101, which is in Phase I clinical trial for the treatment of brain cancer in the United States, and for the treatment of solid tumors in the United Kingdom; and ETS6103, a Phase IIb trial product for depressive disorders. The company also focuses on developing ETX1153c for the treatment of clostridium difficile. e-Therapeutics plc was founded in 2001 and is based in Long Hanborough, the United Kingdom.

26 Employees
Last Reported Date: 05/7/15
Founded in 2001

e-therapeutics plc (ETX) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: 466.0K GBP
Chief Financial Officer, Finance Director and...
Total Annual Compensation: 156.0K GBP
Development Director and Executive Director
Total Annual Compensation: 284.0K GBP
Compensation as of Fiscal Year 2015.

e-therapeutics plc (ETX) Key Developments

e-Therapeutics plc Announces Unaudited Group Earnings Results for the Six Months Ended July 31, 2015

e-Therapeutics plc announced unaudited group earnings results for the six months ended July 31, 2015. For the period, the company reported operating loss of GBP 5,944,000 against GBP 5,324,000 a year ago. Loss before taxation was GBP 5,797,000 against GBP 5,135,000 a year ago. Loss for the period was GBP 4,519,000 against GBP 4,129,000 a year ago. Basic and diluted loss per share was 1.71 pence against 1.56 pence a year ago. Net cash used in operating activities was GBP 3,718,000 against GBP 6,637,000 a year ago. Acquisition of property, plant and equipment was GBP 3,000 against GBP 14,000 a year ago. Acquisition of other intangible assets was GBP 57,000 against GBP 40,000 a year ago.

e-Therapeutics plc. to Report First Half, 2016 Results on Sep 29, 2015

e-Therapeutics plc. announced that they will report first half, 2016 results on Sep 29, 2015

e-Therapeutics plc., H1 2016 Earnings Call, Sep 29, 2015

e-Therapeutics plc., H1 2016 Earnings Call, Sep 29, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ETX:LN 27.50 GBp 0.00

ETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ETX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact E-THERAPEUTICS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at